ALLHAT試験:ハイリスク高血圧患者にはACE阻害薬/Ca拮抗薬と利尿薬どちらが効果的ですか? PMID:12479763


ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

[published correction appears in JAMA 2003 Jan 8;289(2):178] [published correction appears in JAMA. 2004 May 12;291(18):2196]. JAMA. 2002;288(23):2981‐2997. doi:10.1001/jama.288.23.2981














参加者は、約4~8年の追跡調査を計画して、クロルタリドン12.5~25mg/d(n = 15 255)、アムロジピン2.5~10mg/d(n = 9048)、またはリシノプリル10~40mg/d(n = 9054)の投与を受けるように無作為に割り付けられた。











  1. American Heart Association.  2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001.
  2. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review.  Hypertension.1989;13:I36-I44.Google Scholar
  3. Psaty BM, Smith NL, Siscovick DS.  et al.  Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis.  JAMA.1997;277:739-745.Google Scholar
  4. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.  Arch Intern Med.1997;157:2413-2446.Google Scholar
  5. Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control.  J Hypertens.1996;14:929-933.Google Scholar
  6. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease.  Lancet.1990;336:370-371.Google Scholar
  7. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists’ Collaboration.  Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments.  J Hypertens.1998;16:127-137.Google Scholar
  8. SHEP Cooperative Research Group.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA.1991;265:3255-3264.Google Scholar
  9. Staessen JA, Fagard R, Thijs L.  et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.  Lancet.1997;350:757-764.Google Scholar
  10. Yusuf S, Sleight P, Pogue J.  et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators.  N Engl J Med.2000;342:145-153.Google Scholar
  11. PROGRESS Collaborative Group.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.  Lancet.2001;358:1033-1041.Google Scholar
  12. Grimm Jr RH. Antihypertensive therapy: taking lipids into consideration.  Am Heart J.1991;122:910-918.Google Scholar
  13. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Treatment Trialists’ Collaboration.  Lancet.2000;356:1955-1964.Google Scholar
  14. Pahor M, Psaty BM, Alderman MH.  et al.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.  Lancet.2000;356:1949-1954.Google Scholar
  15. Poulter NR. Treatment of hypertension: a clinical epidemiologist’s view.  J Cardiovasc Pharmacol.1991;18(suppl 2):S35-S38.Google Scholar
  16. Neaton JD, Grimm Jr RH, Prineas RJ.  et al.  Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group.  JAMA.1993;270:713-724.Google Scholar
  17. Materson BJ, Reda DJ, Cushman WC.  et al.  Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.  N Engl J Med.1993;328:914-921.Google Scholar
  18. Davis BR, Cutler JA, Gordon DJ.  et al.  Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Am J Hypertens.1996;9:342-360.Google Scholar
  19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  JAMA.2000;283:1967-1975.Google Scholar
  20. Davis BR, Cutler JA, Furberg CD.  et al.  Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.  Ann Intern Med.2002;137:313-320.Google Scholar
  21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.  JAMA.2002;288:2998-3007.Google Scholar
  22. Grimm Jr RH, Margolis KL, Papademetriou V.  et al.  Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Hypertension.2001;37:19-27.Google Scholar
  23. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).  Arch Intern Med.1993;153:154-183.Google Scholar
  24. Levey AS, Bosch JP, Lewis JB.  et al.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group.  Ann Intern Med.1999;130:461-470.Google Scholar
  25. Levey AS, Greene T, Kusek JW.  et al.  A simplified equation to predict glomerular filtration rate from serum creatinine.  J Am Soc Nephrol.2000;11:155A.Google Scholar
  26. Piller LB, Davis BR, Cutler JA.  et al.  Validation of heart failure events in ALLHAT participants assigned to doxazosin.  Curr Control Trials Cardiovasc Med.2002;3:10.Google Scholar
  27. Public Health Service-Health Care Financing Administration.  International Classification of Diseases, Ninth Revision (ICD-9). 6th ed. Bethesda, Md: US Dept of Health and Human Services; 2001. DHHS Publication No. (PHS) 80-1260.
  28. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control.  J Am Stat Assoc.1955;50:1096-1121.Google Scholar
  29. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. New York, NY: Springer-Verlag; 1997.
  30. Davis BR, Hardy RJ. Upper bounds for type I and II error rates in conditional power calculations.  Commun Stat.1990;19:3571-3584.Google Scholar
  31. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials.  Biometrika.1983;70:659-663.Google Scholar
  32. Hansson L, Lindholm LH, Ekbom T.  et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study.  Lancet.1999;354:1751-1756.Google Scholar
  33. Brown MJ, Palmer CR, Castaigne A.  et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).  Lancet.2000;356:366-372.Google Scholar
  34. MacMahon S, Neal B. Differences between blood-pressure-lowering drugs.  Lancet.2000;356:352-353.Google Scholar
  35. Kostis JB, Davis BR, Cutler J.  et al.  Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group.  JAMA.1997;278:212-216.Google Scholar
  36. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension.  Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding.  J Hypertens.1997;15:105-115.Google Scholar
  37. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease.  Circulation.1995;92:1326-1331.Google Scholar
  38. Agodoa LY, Appel L, Bakris GL.  et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.  JAMA.2001;285:2719-2728.Google Scholar
  39. Hall WD, Kusek JW, Kirk KA.  et al.  Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.  Am J Kidney Dis.1997;29:720-728.Google Scholar
  40. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease.  Arch Intern Med.1994;154:1185-1202.Google Scholar
  41. Lonn EM, Yusuf S, Jha P.  et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.  Circulation.1994;90:2056-2069.Google Scholar
  42. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management.  Am J Hypertens.1999;12:205S-213S.Google Scholar
  43. Jafar TH, Schmid CH, Landa M.  et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data.  Ann Intern Med.2001;135:73-87.Google Scholar
  44. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators.  N Engl J Med.1992;327:685-691.Google Scholar
  45. Collins R, Peto R, MacMahon S.  et al.  Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.  Lancet.1990;335:827-838.Google Scholar
  46. MacMahon S, Peto R, Cutler J.  et al.  Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.  Lancet.1990;335:765-774.Google Scholar
  47. Staessen JA, Byttebier G, Buntinx F.  et al.  Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial: Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators.  JAMA.1997;278:1065-1072.Google Scholar
  48. Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist’s point of view.  Pathol Biol (Paris).1999;47:594-603.Google Scholar
  49. Saunders E, Weir MR, Kong BW.  et al.  A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.  Arch Intern Med.1990;150:1707-1713.Google Scholar
  50. Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population.  Endocrinol Metab Clin North Am.1997;26:125-144.Google Scholar
  51. Cushman WC, Reda DJ, Perry HM.  et al.  Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States.  Arch Intern Med.2000;160:825-831.Google Scholar
  52. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.  N Engl J Med.2001;344:1351-1357.Google Scholar
  53. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group.  J Card Fail.1999;5:178-187.Google Scholar
  54. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.  J Am Coll Cardiol.2002;40:311-317.Google Scholar
  55. Manolio TA, Cutler JA, Furberg CD.  et al.  Trends in pharmacologic management of hypertension in the United States.  Arch Intern Med.1995;155:829-837.Google Scholar

チェック項目(ランダム化比較試験) よりダウンロードできます




Pステージ1またはステージ2の高血圧症で、CHDイベントのリスク因子を1つ以上追加した55歳以上の男女33,357人(平均年齢66.9歳 , 女性47%)
E1アムロジピン2.5~10mg/d(n = 9048)を投与
E2リシノプリル10~40mg/d(n = 9054)を投与
Cクロルタリドン12.5~25mg/d(n = 15 255)を投与








追跡期間(追跡率) 4.9年(クロルタリドン群97.3%、アムロジピン群97.2%、リシノプリル群97%)
解析方法 ITT解析 ☐per protocol 解析 ▢FAS解析


Pステージ1またはステージ2の高血圧症で、CHDイベントのリスク因子を1つ以上追加した55歳以上の男女33,357人(平均年齢66.9歳 , 女性47%)
E1アムロジピン2.5~10mg/d(n = 9048)を投与
E2リシノプリル10~40mg/d(n = 9054)を投与
Cクロルタリドン12.5~25mg/d(n = 15 255)を投与
E1798 / 9048
E2796 / 9054
C1362 / 15255
相対危険度[95%CI]E1/C = 0.98 ( 0.90-1.07 )
E2/C = 0.99 ( 0.91-1.08 )








メールアドレスが公開されることはありません。 * が付いている欄は必須項目です

このサイトはスパムを低減するために Akismet を使っています。コメントデータの処理方法の詳細はこちらをご覧ください